SCHEMBL3153994

SCHEMBL3153994

NC(=O)c1ccc(C[CH]C(=O)NCc2ccc(N)nc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MKNK1 Q9BUB5 1/20 0.48
MKNK2 Q9HBH9 1/20 0.48
HDAC1 Q13547 3/20 0.44
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
GABRA4 P48169 2/20 0.42
GABRE P78334 2/20 0.42
GABRA6 Q16445 2/20 0.42
GABRG1 Q8N1C3 2/20 0.42
GABRG3 Q99928 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3141272 0.87 F10 (0.43) NNMTSMN1; SMN2HDAC1GABRPGABRD
SCHEMBL3154818 0.86 NAMPT (0.55) HDAC1GABRPGABRDGABRA1GABRB1
SCHEMBL3139636 0.85 GABRP (0.40) NNMTSMN1; SMN2HDAC1GABRPGABRD
SCHEMBL3144601 0.83 GABRP (0.39) SMN1; SMN2HDAC1GABRPGABRDGABRA1
SCHEMBL3154969 0.82 NAMPT (0.39) NNMTSMN1; SMN2HDAC1GABRPGABRD
SCHEMBL3139983 0.82 HDAC1 (0.39) HDAC1GABRPGABRDGABRA1GABRB1
SCHEMBL3140045 0.81 NAMPT (0.43) NNMTSMN1; SMN2HDAC1GABRPGABRD
SCHEMBL3140763 0.80 TSHR (0.44) SMN1; SMN2HDAC1GABRPGABRDGABRA1
SCHEMBL3149644 0.80 NAMPT (0.44) HDAC1GABRPGABRDGABRA1GABRB1
SCHEMBL3153720 0.78 F2 (0.38) HDAC1GABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100076015-A1 Aminopyridine Derivatives VANTIA LIMITED (GB) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076015-A1 Aminopyridine Derivatives CHRM1, ARG1, ARG2 NNMT 400/4885SMN1; SMN2 3460/4885MKNK1 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.